Amneal

FYLNETRA

Manufacturer:

Amneal

Fylnetra HCPCS:

Q5130

HCPCS Code Descriptor:

Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg

Category:

Q Code

Fylnetra NDCs:

70121-1627-01

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic/Specialty Status:

Single-Source

Package Type:

Syringe

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Fylnetra:

FYLNETRA is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Amneal and administered via the Subcutaneous route of administration. The Q Code: Q5130 is aligned to the drug FYLNETRA.

Fylnetra (pegfilgrastim) is a protein that aids the production of white blood cells (neutrophils) and is used to help prevent the lack of neutrophils in a patient. Fylnetra is produced by Amneal Pharmaceuticals and is biosimilar to the medication Neulasta (J2506). This drug was assigned the HCPCS code Q5130 in April 2023. Patient assistance programs for Flynetra can be found through the Amneal Patient Assistance Program.

ACCESS PRICING AND MORE BY REGISTERING

Q5130 Added Date:

April 1, 2023

Q5130 Effective Date:

April 1, 2023

Q5130 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Fylnetra billing and coding information.
Fylnetra patient assistance information can be found through The Amneal Patient Assistance Program at the URL: https://www.amneal.com/about/responsibility/patient-assistance-programs/
FYLNETRA prescribing information can be found at the link below:
Information regarding FYLNETRA’s side effects can be found at MedlinePlus